Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: Relapse rates and functional outcome

Journal of Clinical Psychiatry

Volumn 68, Issue 5, 2007, Pages 654-661

  Wunderink, Lex ^a   Nienhuis, Fokko J ^a   Sytema, Sjoerd ^a   Slooff, Cees J ^b   Knegtering, Rikus ^a   Wiersma, Durk ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Mental Health Care Drenthe   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MENTAL HEALTH ORGANIZATION; NETHERLANDS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; RECURRENCE RISK; SYMPTOMATOLOGY; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RECURRENCE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 34249715417     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0502     Document Type: Article

References (34)

1. Jolley AG, Hirsch SR, Morrison E, et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990;301:837-842
2. Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry 1991;48:333-339
3. Carpenter WT Jr, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147:1138-1148
4. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995;52:173-188
5. Gitlin M, Nuechterlein K, Subotnik KL et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001;158:1835-1842
6. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247
7. Kane JM. Management strategies for the treatment of schizophrenia. J Clin Psychiatry 1999;60(suppl 12):13-17
8. Bosveld-van Haandel LJ, Slooff CJ, van den Bosch RJ. Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments. Acta Psychiatr Scand 2001; 103:335-346
9. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. 2nd ed. Washington, DC: American Psychiatric Association; 2004
10. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68
11. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000;61(suppl 4):21-26
12. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 1686-1696
13. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19-28
14. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59:1021-1026
15. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001; 52:503-517
16. Knegtering H, van der Moolen AE, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003;28(suppl 2):109-123
17. Wyatt RJ, Damiani LM, Henter ID. First-episode schizophrenia: early intervention and medication discontinuation in the context of course and treatment. Br J Psychiatry Suppl 1998;172:77-83
18. Shepherd M, Watt D, Falloon I, et al. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med Monogr Suppl 1989;15:1-46
19. Wiersma D, Nienhuis FJ, Slooff CJ, et al. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998;24:75-85
20. Wieselgren IM, Lindstrom LH. A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients: relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment. Acta Psychiatr Scand 1996;93:9-19
21. Viguera AC, Baldessarini RJ, Hegarty JD, et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997;54:49-55
22. Gaebel W, Janner M, Frommann N, et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 2002;53:145-159
23. World Health Organization. Schedules for Clinical Assessment in Neuropsychiatry. Version 2.1. Geneva, Switzerland: World Health Organization; 1992
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
25. Kay S, Fiszbein A, Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
26. Lambert TJ, Cock N, Alcock SJ, et al. Measurement of antipsychotic- induced side effects: support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Hum Psychopharmacol 2003;18:405-111
27. Day JC, Wood G, Dewey M, et al. A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients. Br J Psychiatry 1995;166:650-653
28. Wiersma D, de long A, Kraaijkamp HJM, et al. GSDS II, The Groningen Social Disabilities Schedule, second version. Groningen, the Netherlands: Department of Psychiatry, Rijksuniversiteit Groningen; 1990
29. Wiersma D, DeJong A, Ormel J. The Groningen Social Disabilities Schedule: development, relationship with the I.C.I.D.H. and psychometric properties. Int J Rehabil Res 1988;11:213-224
30. O'Carroll RE, Smith K, Couston M, et al. A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation. Qual Life Res 2000;9:121-124
31. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-149
32. Wunderink L, Nienhuis FJ, Sytema S, et al. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull 2006 August 7 [Epub ahead of print]
33. Jolley AG, Hirsch SR, McRink A, et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ 1989;298:985-990
34. Johnstone EC, Macmillan JF, Frith CD, et al. Further investigation of the predictors of outcome following 1st schizophrenic episodes. Br J Psychiatry 1990;157:182-189